TB-500 Fragment 17-23: The Active Actin-Binding Domain of Thymosin Beta-4

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is TB-500 Fragment 17-23?

TB-500 Fragment 17-23 is a heptapeptide (seven-amino-acid peptide) with the sequence LKKTETQ (Leu-Lys-Lys-Thr-Glu-Thr-Gln), representing residues 17-23 of the 43-amino-acid thymosin beta-4 (TB-4) protein. This specific region constitutes the actin-binding domain of TB-4 and is the minimal sequence required for G-actin (monomeric actin) interaction. The fragment has attracted research interest as a potentially more targeted and stable alternative to the full-length TB-500 (thymosin beta-4) for tissue repair applications.

The rationale for studying this fragment rather than the complete protein centers on the principle that the critical biological activity may reside in a specific structural domain. If the actin-binding domain alone recapitulates the tissue repair effects attributed to full-length TB-4, it would offer advantages in manufacturing simplicity, stability, and potentially more predictable pharmacology.

Mechanism of Action

The LKKTETQ sequence mediates TB-4's interaction with monomeric G-actin through electrostatic and hydrogen bonding interactions. This binding has several important downstream consequences for cell biology and tissue repair:

Actin Dynamics

• G-actin sequestration: By binding G-actin monomers, the fragment prevents their incorporation into F-actin (filamentous actin) polymers. This maintains a pool of available monomers, which paradoxically promotes actin filament dynamics by facilitating rapid turnover rather than static polymer accumulation.
• Cell migration: Dynamic actin remodeling is essential for cell migration. Cells at wound edges must extend lamellipodia and filopodia (actin-driven protrusions), detach from the substrate at the trailing edge, and move into the wound space. The actin-sequestering activity of the LKKTETQ domain supports this process.
• Cytoskeletal plasticity: Beyond migration, actin dynamics influence cell shape, division, endocytosis, and intracellular transport — all processes relevant to tissue repair and regeneration.

Fragment vs. Full-Length TB-4

Full-length TB-4 possesses biological activities beyond actin binding, including anti-inflammatory signaling, anti-apoptotic effects, and gene expression modulation. The key question for fragment research is whether the actin-binding activity alone is sufficient to drive meaningful tissue repair, or whether the additional domains of TB-4 contribute essential complementary functions. Published evidence suggests that the LKKTETQ fragment retains significant cell migration-promoting activity but may not fully recapitulate all of TB-4's tissue repair properties.

Research Findings

Actin Binding Studies

The interaction between the LKKTETQ sequence and G-actin has been characterized by X-ray crystallography, NMR spectroscopy, and biochemical binding assays. The fragment binds G-actin with measurable affinity, though with lower binding strength than the full-length TB-4 molecule, which makes additional contacts with actin through regions outside the 17-23 domain.

Cell Migration Assays

In vitro cell migration studies (scratch/wound healing assays, Boyden chamber assays) have demonstrated that the TB-500 Fragment 17-23 promotes migration of various cell types including endothelial cells, keratinocytes, and fibroblasts. The magnitude of the migration-promoting effect has generally been reported as less than that of full-length TB-4 in side-by-side comparisons, but significantly greater than untreated controls.

In Vivo Studies

In vivo data specifically for the isolated 17-23 fragment are limited compared to the extensive literature on full-length TB-4. Some wound healing studies in animal models have reported accelerated closure with fragment treatment, but the body of evidence is substantially smaller than for the parent molecule. This represents a significant gap in the research literature.

Safety and Tolerability

As a short peptide composed of common amino acids, TB-500 Fragment 17-23 is expected to have low intrinsic toxicity and rapid metabolic degradation. No significant adverse effects have been reported in the limited published research. However, formal toxicology studies have not been published, and the safety profile remains less characterized than that of full-length TB-4, which itself has not completed comprehensive human safety evaluation.

Regulatory Status

TB-500 Fragment 17-23 is not FDA-approved for any indication. It is available through research peptide suppliers. Full-length TB-4 (under the name RGN-352 and other development names) has been investigated in clinical trials for cardiac repair and corneal healing, but the isolated 17-23 fragment has not entered formal clinical development. Users should be aware that this is a research compound without established clinical validation.